Gastrointestinal Diseases  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
COOPERATE-1, NCT01374451 / 2010-023183-40: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Terminated
2
160
Japan, US, Canada, Europe, RoW
Everolimus, RAD001, Pasireotide LAR, SOM230 LAR
Novartis Pharmaceuticals
Islet Cell Tumor
02/15
02/15
NCT01488487: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Completed
2
24
US
Everolimus, Afinitor, RAD001, Pasireotide, SOM230, Pasireotide LAR, Pasireotide s.c.
UNC Lineberger Comprehensive Cancer Center, Novartis Pharmaceuticals
Advanced Adult Hepatocellular Carcinoma
03/15
03/15
NCT00958841 / 2008-007348-32: Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Terminated
2
118
US, Canada, Europe, RoW
pasireotide LAR, SOM230
Novartis Pharmaceuticals
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
06/15
06/15
NCT01637272 / 2012-001534-34: Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

Completed
2
43
US, Europe
SOM230, pasireotide
Novartis Pharmaceuticals
Dumping Syndrome
08/15
08/15
NCT01639352: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

Completed
2
20
US
SOM230, Pasireotide LAR, SOM230C
Lynn Feun
Hepatocellular Carcinoma
08/16
02/17

Download Options